JP2004526745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004526745A5 JP2004526745A5 JP2002578899A JP2002578899A JP2004526745A5 JP 2004526745 A5 JP2004526745 A5 JP 2004526745A5 JP 2002578899 A JP2002578899 A JP 2002578899A JP 2002578899 A JP2002578899 A JP 2002578899A JP 2004526745 A5 JP2004526745 A5 JP 2004526745A5
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- group
- composition
- carbons
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 27
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims 16
- 229930195729 fatty acid Natural products 0.000 claims 16
- 239000000194 fatty acid Substances 0.000 claims 16
- 150000004665 fatty acids Chemical class 0.000 claims 16
- 229920006395 saturated elastomer Polymers 0.000 claims 15
- 125000002252 acyl group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 125000005313 fatty acid group Chemical group 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 210000000577 adipose tissue Anatomy 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000001276 controlling effect Effects 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 230000037406 food intake Effects 0.000 claims 5
- 235000012631 food intake Nutrition 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000021407 appetite control Nutrition 0.000 claims 2
- 230000033228 biological regulation Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004129 fatty acid metabolism Effects 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 229960004488 linolenic acid Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000018770 reduced food intake Nutrition 0.000 claims 1
- 230000013333 regulation of fatty acid metabolic process Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27954201P | 2001-03-27 | 2001-03-27 | |
| US33628901P | 2001-10-31 | 2001-10-31 | |
| PCT/US2002/009773 WO2002080860A2 (en) | 2001-03-27 | 2002-03-27 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004526745A JP2004526745A (ja) | 2004-09-02 |
| JP2004526745A5 true JP2004526745A5 (enExample) | 2005-12-22 |
Family
ID=26959730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002578899A Pending JP2004526745A (ja) | 2001-03-27 | 2002-03-27 | 体脂肪を減らし脂肪酸の代謝を変調する方法、化合物および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6911474B2 (enExample) |
| EP (1) | EP1408945A4 (enExample) |
| JP (1) | JP2004526745A (enExample) |
| KR (1) | KR20030087657A (enExample) |
| CN (1) | CN1523982A (enExample) |
| AU (1) | AU2002338329B2 (enExample) |
| CA (1) | CA2442683A1 (enExample) |
| EA (1) | EA006556B1 (enExample) |
| IL (1) | IL158131A0 (enExample) |
| MX (1) | MXPA03008823A (enExample) |
| WO (1) | WO2002080860A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006556B1 (ru) | 2001-03-27 | 2006-02-24 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот |
| DE10129693A1 (de) * | 2001-06-22 | 2003-01-02 | Jan Loock | Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums |
| CA2475630C (en) | 2002-02-12 | 2011-01-18 | Hunza Di Pistolesi Elvira & C. S.A.S. | N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| US20050101542A1 (en) * | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
| US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
| US20040157932A1 (en) * | 2002-11-18 | 2004-08-12 | Natural Asa, | Supplements and foods comprising oleylethanolamide |
| US7083933B1 (en) | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| EP1677780A4 (en) * | 2003-10-16 | 2007-05-02 | Univ California | DIETARY AND OTHER FOODS, COMPOUNDS AND METHOD FOR REDUCING BODY FAT, APPETIZING AND MODULATING THE FATTY ACID CHANGES |
| EP1570752B1 (en) * | 2004-03-06 | 2008-07-02 | Cognis IP Management GmbH | Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme |
| JP2006061086A (ja) * | 2004-08-27 | 2006-03-09 | Morishita Jintan Kk | 脂肪代謝改善効果を有する被験試料のスクリーニング方法 |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2007006319A2 (en) * | 2005-07-14 | 2007-01-18 | Rheoscience A/S | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| DE602007010420D1 (de) | 2006-04-11 | 2010-12-23 | Arena Pharm Inc | Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| US20090208513A1 (en) * | 2007-09-07 | 2009-08-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions |
| ES2291147B1 (es) * | 2007-10-15 | 2008-11-01 | Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) | Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion. |
| EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
| BRPI0912774A2 (pt) * | 2008-05-19 | 2017-05-23 | Nestec Sa | métodos para reduzir absorção de lipídio por um animal |
| CN102791145A (zh) * | 2010-03-24 | 2012-11-21 | 雀巢产品技术援助有限公司 | 增强可食用组合物的适口性的方法 |
| US9511042B2 (en) | 2010-07-02 | 2016-12-06 | Helix Biomedix Inc. | N-acyl amino acid derivatives for treating skin conditions such as cellulite |
| CA2866067C (en) | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
| CA2835429A1 (en) * | 2011-05-10 | 2012-11-15 | Nestec S.A. | Methods and compositions for promoting lean body mass growth |
| AU2012253701A1 (en) * | 2011-05-10 | 2013-11-21 | Nestec S.A. | Methods and compositions for preserving lean body mass during weight loss |
| US8426471B1 (en) * | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| CN102579414A (zh) * | 2012-01-29 | 2012-07-18 | 厦门大学 | 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途 |
| WO2013160492A1 (es) * | 2012-04-24 | 2013-10-31 | Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) | Terapia combinada para el tratamiento de enfermedades metabólicas |
| US9221747B2 (en) | 2012-04-25 | 2015-12-29 | Iowa State University Research Foundation, Inc. | Method of making fatty acid N-acylalkanolamines |
| CN102675141A (zh) * | 2012-05-04 | 2012-09-19 | 庄信修 | N-(2-羟基乙基)芥酰胺及其制备与用途 |
| WO2014037546A1 (en) | 2012-09-07 | 2014-03-13 | Nestec S.A. | Oleoylethanolamide compositions |
| CN102824338A (zh) * | 2012-09-18 | 2012-12-19 | 厦门大学 | s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途 |
| WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| CN103113253A (zh) * | 2013-01-28 | 2013-05-22 | 国家海洋局第三海洋研究所 | 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用 |
| ES2498521B1 (es) * | 2013-02-20 | 2015-08-18 | Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) | Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad |
| NO2753788T3 (enExample) | 2013-05-10 | 2018-06-16 | ||
| US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| PH12018000077B1 (en) | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| PH12018000227A1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| WO2024124172A1 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8505569D0 (sv) * | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
| US5506224A (en) * | 1991-12-31 | 1996-04-09 | Lifegroup S.P.A. | N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes |
| US5679667A (en) * | 1992-04-24 | 1997-10-21 | Lifegroup S.P.A. | Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve |
| US5602164A (en) * | 1992-04-28 | 1997-02-11 | Senyorina Ltd. | Anti-obesity drugs |
| US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
| IL103932A (en) | 1992-11-30 | 1997-02-18 | Yissum Res & Dev | Fatty acid and pharmaceutical compositions containing them |
| US5618955A (en) * | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
| US5631297A (en) * | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
| IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| IT1274783B (it) * | 1994-12-15 | 1997-07-24 | Antonio Picarelli | Preparato per il trattamento dell'obesita' |
| CA2215387A1 (en) * | 1995-03-20 | 1996-09-26 | Michael R. Briggs | Modulators of ob gene and screening methods therefor |
| US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| ES2217392T3 (es) | 1996-02-02 | 2004-11-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
| US6090836A (en) | 1996-02-02 | 2000-07-18 | Merck & Co., Inc. | Benzisoxazole-derived antidiabetic compounds |
| US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US5803916A (en) | 1996-03-19 | 1998-09-08 | Vital-Tech Ltd. | Body and joints massage device |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US5830916A (en) * | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| US5925672A (en) | 1996-12-06 | 1999-07-20 | Neurosciences Research Foundation, Inc. | Methods of treating mental diseases, inflammation and pain |
| US6090839A (en) | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
| US6160000A (en) | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
| US5985282A (en) * | 1997-01-22 | 1999-11-16 | Hpf, L.L.C. | Herbal appetite suppressant and weight loss composition |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| CA2330681C (en) | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US6274608B1 (en) | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
| GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
| US6359010B1 (en) * | 1999-11-23 | 2002-03-19 | Thomas D. Geracioti, Jr. | Methods of treating anxiety and mood disorders with oleamide |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| US6974568B2 (en) | 2000-05-23 | 2005-12-13 | The Regents Of The University Of California | Treatment for cough |
| EA006556B1 (ru) | 2001-03-27 | 2006-02-24 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот |
| US7048941B2 (en) | 2001-03-30 | 2006-05-23 | New World Enterprizes, Inc. | Chocolate composition as delivery system for nutrients and medications |
| JP5093967B2 (ja) * | 2001-04-06 | 2012-12-12 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 睡眠時の自律的安定性に関するカンナビノイドの機能的役割 |
| CA2455555A1 (en) * | 2001-07-31 | 2003-02-13 | The Scripps Research Institute | Animal model for fatty acid amide-related neurobehaviors |
| EP1472215A4 (en) | 2002-02-08 | 2007-05-09 | Bristol Myers Squibb Co | (OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS |
| US20040157932A1 (en) | 2002-11-18 | 2004-08-12 | Natural Asa, | Supplements and foods comprising oleylethanolamide |
-
2002
- 2002-03-27 EA EA200301057A patent/EA006556B1/ru not_active IP Right Cessation
- 2002-03-27 AU AU2002338329A patent/AU2002338329B2/en not_active Ceased
- 2002-03-27 CA CA002442683A patent/CA2442683A1/en not_active Abandoned
- 2002-03-27 CN CNA028093410A patent/CN1523982A/zh active Pending
- 2002-03-27 US US10/112,509 patent/US6911474B2/en not_active Expired - Lifetime
- 2002-03-27 JP JP2002578899A patent/JP2004526745A/ja active Pending
- 2002-03-27 IL IL15813102A patent/IL158131A0/xx unknown
- 2002-03-27 WO PCT/US2002/009773 patent/WO2002080860A2/en not_active Ceased
- 2002-03-27 KR KR10-2003-7012669A patent/KR20030087657A/ko not_active Abandoned
- 2002-03-27 EP EP02763872A patent/EP1408945A4/en not_active Withdrawn
- 2002-03-27 MX MXPA03008823A patent/MXPA03008823A/es active IP Right Grant
-
2005
- 2005-04-04 US US11/099,134 patent/US7423066B2/en not_active Expired - Lifetime
-
2008
- 2008-06-16 US US12/140,156 patent/US20090005447A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004526745A5 (enExample) | ||
| CA2607247A1 (en) | .alpha.-substituted dha derivatives | |
| JP3103588B2 (ja) | リポプロテイン（ａ）低下剤 | |
| JP4845332B2 (ja) | 抗炎症性及び免疫調整アミノ酸誘導体、その調製及び使用 | |
| JP2012526094A5 (enExample) | ||
| JP2019510039A5 (enExample) | ||
| JP2007512376A5 (enExample) | ||
| ES2249257T3 (es) | Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa. | |
| JP7130818B2 (ja) | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 | |
| US8338481B2 (en) | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer | |
| JP5552314B2 (ja) | 新規脂質化合物 | |
| JP2009530398A5 (enExample) | ||
| JP2004524312A5 (enExample) | ||
| JP2009530393A5 (enExample) | ||
| JPWO2021244831A5 (enExample) | ||
| JP2017513824A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| RU2005107416A (ru) | Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии | |
| AU2020200796A1 (en) | Novel n-3 immunoresolvents: structures and actions | |
| JP2020100623A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| JP2018515463A5 (enExample) | ||
| US9505709B2 (en) | Compositions and methods relating to ionic salts of peptides | |
| JPH1036365A5 (enExample) |